Melphalan drug delivery system - Delcath Systems

Drug Profile

Melphalan drug delivery system - Delcath Systems

Alternative Names: CS-PHP-Melphalan; Delcath Hepatic CHEMOSAT Delivery System for Melphalan; Generation Two CHEMOSAT Delivery System for Melphalan; Melblez Kit; Melphalan/HDS; Melphalan/Hepatic Delivery System

Latest Information Update: 30 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Yale University School of Medicine
  • Developer Delcath Systems
  • Class Antineoplastics; Aromatic amino acids; Myeloablative agonists; Nitrogen mustard compounds; Small molecules
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma; Neuroendocrine tumours; Cholangiocarcinoma; Malignant melanoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Liver metastases
  • Phase II/III Cholangiocarcinoma
  • Phase II Hepatocellular carcinoma

Most Recent Events

  • 27 Jul 2018 9245844: kdm updated
  • 09 Jul 2018 Delcath Systems plans a registration trial for intrahepatic Cholangiocarcinoma
  • 16 May 2018 The German Guidelines Program in Oncology includes CHEMOSAT® in German Treatment Guidelines for Liver metastases from melanoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top